Patent · US Active

Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor

US11590128B2 · kind B2 · utility

2Cited by

10References

7Claims

0Family size

Assignees

Genentech, Inc. · US
Hoffmann-La Roche Inc. · US
Abb Vie Inc. · US

Inventors

Deepak Sampath · South San Francisco, US
Christian Klein · Iffeldorf, DE
Wayne Fairbrother · South San Francisco, US
Sari L. Heitner Enschede · River Forest, US
Rod A. Humerickhouse · Highland Park, US
Andrew W. Roberts · Melbourne, AU
John F. Seymour · Melbourne, AU

Key dates

Filing date	Jun 7, 2022
Grant date	Feb 28, 2023
Priority date	—
Expiry date	Jun 7, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.